| Titre : | Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. (2001) |
| Auteurs : | Bruce-R SCHACKMAN ; Kenneth-A FREEDBERG ; Sue-J GOLDIE ; HONG ZHANG . (.) ; Elena LOSINA ; Milton-C WEINSTEIN ; Center for Risk Analysis. Department of Health Policy and Management. Harvard School of Public Health. Boston. MA. USA ; Department of Epidemiology and Biostatistics. Boston University School of Public Health. Boston. USA |
| Type de document : | Article |
| Dans : | American journal of public health (vol. 91, n° 9, 2001) |
| Pagination : | 1456-1463 |
| Langues: | Anglais |
| Mots-clés : | Médicament antiviral ; VIH ; Rétrovirus ; Virus ; Thérapeutique ; Thérapeutique médicamenteuse ; Sida ; Virose ; Infection ; Assurance maladie ; Protection sociale ; Analyse coût efficacité ; Economie santé ; Pauvreté ; Adulte ; Homme ; Politique sociale ; Immunopathologie ; Budget ; Etats Unis ; Amérique ; Amérique du Nord ; Medicaid |
| Résumé : | [BDSP. Notice produite par INIST-CNRS plMR0xe3. Diffusion soumise à autorisation]. Objectives. This study was designed to examine the societal cost-effectiveness and the impact on government payers of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. Methods. A state-transition simulation model of HIV disease was used. Data were derived from the Multicenter AIDS Cohort Study, published randomized trials, and medical care cost estimates for all government payers and for Massachusetts, New York, and Florida. Results. Quality-adjusted life expectancy increased from 7.64 years with therapy initiated at 200 CD4 cells/pL to 8.21 years with therapy initiated at 500 CD4 cells/muL Initiating therapy at 500 CD4/muL was a more efficient use of resources than initiating therapy at 200 CD4/pL and had an incremental cost-effectiveness ratio of $17 300 per quality-adjusted life-year gained, compared with no therapy. Costs to state payers in the first 5 years ranged from $5500 to $24 900 because of differences among the states in the availability of federal funds for AIDS drug assistance programs. Conclusions. Antiretroviral therapy initiated at 500 CD4 cells/pL is cost-effective from a societal perspective compared with therapy initiated later. States should consider Medicaid waivers to expand access to early therapy. |
Service Documentation EHESP
Me connecter
PORTAIL DOCUMENTAIRE
École des hautes études en santé publique
Catalogue
Multi-bases
Accueil
Sélection de la langue
Adresse
Service Documentation EHESPBibliothèque Rennes Avenue du Professeur Léon Bernard – CS 74312 – 35043 Rennes Cedex Bibliothèque MSSH Paris 20 avenue George Sand - 93210 La Plaine Saint-Denis
France
Bibliothèque Rennes : 02 99 02 29 50 Bibliothèque MSSH Paris : 02 99 02 24 50
contact